Nonetheless, adoptive T cell transfer studies, using TCR transgenic T cells and ID8 ovarian carcinoma and EL4 lymphoma cells modified to express model antigens, demonstrated an enhanced capacity of PTPN22-deficient CD8+ T cells to clear established tumours in mice [88,93]. The gene discussed is PTPN22; the disease is neoplasm.